Cardiology in review
Finerenone and Its Cardiorenal Protective Effects: A Meta-Analysis of 21,731 Patients From Randomized Trials.
Bibeka Rai, Salman Farooq Dar, Moaz Alowami, Roshail Bin Sajjad, Trishtha Agarwal, Muhammad Haris Khan, Salman Riaz Mubarak Ali, Ghuncha Kamran, Renju Philip Thomas, Nipun Sanka Bandara Adikari Mudiyanselage, Bashar AlQudah, Yumna Aziz Khan, Nitish Behary Paray, Maryam Shahzad, Mushood Ahmed
Published: 202510.1097/CRD.0000000000001068
Abstract
Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has emerged as a promising therapy for patients with diabetes, chronic kidney disease, heart failure (HF), or diabetes. We aimed to summarize the current evidence on its cardiovascular…
Preview only. Read the full abstract at the source